JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD Pharm. D V Year PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS Previous Question Paper (November/December - 2021 - R08)

Pharmacoepidemiology emerged as a distinct discipline in the late 20th century, primarily driven by the need to bridge the gap between clinical pharmacology and epidemiology. Its history is rooted in the 1960s and 1970s, following major drug safety crises such as the thalidomide tragedy, which exposed the limitations of pre-marketing clinical trials in detecting rare or long-term adverse effects. The formalization of the field gained momentum in the 1980s with the establishment of the International Society of Pharmacoepidemiology (ISPE) and the publication of seminal texts that defined the application of epidemiological methods to study drug use and outcomes in large populations.

Aims of Pharmacoepidemiology:

• To quantify the frequency and distribution of drug use in populations.
• To identify and evaluate the risks and benefits of medications in real-world settings.
• To understand the patterns of drug utilization and prescribing behaviors.
• To provide evidence for regulatory decision-making regarding drug safety and market authorization.
• To improve patient safety by minimizing preventable adverse drug reactions.

Applications of Pharmacoepidemiology:

1. Post-marketing Surveillance: Monitoring drugs after they reach the market to detect rare adverse effects that were not apparent during clinical trials.
2. Drug Utilization Studies: Analyzing how drugs are prescribed and used, which helps in identifying irrational prescribing, drug-drug interactions, and adherence issues.
3. Comparative Effectiveness Research: Evaluating the relative efficacy and safety of different therapeutic options to guide clinical guidelines and health policy.
4. Signal Detection: Using large healthcare databases to identify potential safety signals that warrant further investigation.
5. Pharmacoeconomic Integration: Providing data on real-world outcomes that inform cost-effectiveness analyses and health technology assessments.

Teratogenic studies in pharmacoepidemiology focus on identifying and quantifying the risk of congenital malformations or developmental abnormalities following maternal exposure to medications during pregnancy. These studies are critical because the placenta does not act as a complete barrier, and the fetus is highly susceptible to chemical insults during organogenesis (typically the first trimester).

Key study designs used include:

• Case-Control Studies: These are the most common approach for rare birth defects. Researchers compare the medication exposure history of mothers who gave birth to infants with specific malformations (cases) against mothers of healthy infants (controls).
• Cohort Studies: These involve identifying pregnant women exposed to a specific drug and following them through pregnancy to observe outcomes. While better for assessing multiple outcomes, they require large sample sizes to detect rare defects.
• Pregnancy Registries: These are prospective observational studies that collect data on drug exposure during pregnancy and track the health of the infant, providing essential safety data for drugs where human data is initially limited.

These studies differ from regular pharmacoepidemiology in several fundamental ways:

• Exposure Sensitivity: The timing of exposure is critical; a drug may be teratogenic only during a specific window of embryonic development, whereas regular studies often focus on chronic or acute exposure effects in adults.
• Outcome Complexity: Outcomes are often rare, heterogeneous, and may not manifest until later in childhood, requiring long-term follow-up compared to the immediate or short-term clinical endpoints (like blood pressure or infection clearance) seen in standard studies.
• Confounding by Indication: In pregnancy, the underlying maternal disease itself may be a risk factor for birth defects, making it difficult to isolate the drug's effect from the disease's effect.
• Ethical Constraints: Clinical trials are rarely conducted in pregnant populations due to ethical concerns, making observational pharmacoepidemiological data the primary source of evidence for fetal safety.
• Statistical Challenges: Due to the low prevalence of most birth defects, these studies require specialized statistical techniques to handle small numbers of events and to control for maternal factors like age, smoking, and nutritional status.